New Screening Criteria for HBV Reactivation in Myeloma
1Identified risk criteria for HBV reactivation during blood cancer treatment.
2Seoul St. Mary's team reveals world-first high-risk screening indicators.
3Cancer patients can now receive safer treatment without liver damage fears.
📖 Easy Explanation
🔍 Background
Treating multiple myeloma, a type of blood cancer, often reactivates dormant Hepatitis B virus (HBV), causing liver damage. Predicting which patients are at risk was previously difficult.
📌 Key Points
Professors at Seoul St. Mary's Hospital identified the first criteria to predict high-risk patients. They created a guide on monitoring liver levels and viral status when using specific immunotherapies.
💡 Why It Matters
Elderly cancer patients can now avoid sudden liver complications. Doctors can identify high-risk individuals early and prescribe preventive medicine, allowing patients to focus on recovery.
📚 Glossary
다발성골수종 (Dabalseong Golsujong)Multiple Myeloma, a type of blood cancer originating in bone marrow
면역항암치료 (Myeonyeok Hangam Chiryo)Immunotherapy that boosts the immune system to attack cancer cells
재활성화 (Jaehwal Seonghwa)Reactivation of a dormant virus in the body, leading to replication